ArticleThe Pediatric infectious disease journal2022
Antimicrobial Susceptibility Profiles Among Neonatal Early-onset Sepsis Pathogens.
Article in The Pediatric infectious disease journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Antibiotic Therapy for the Prevention and Treatment of Neonatal Sepsis.Clinics in perinatology · 2026Review
- Evolution of Antimicrobial Resistance in Neonatal Sepsis: A Narrative Review.Antibiotics (Basel, Switzerland) · 2026Review
- Risk Factors and Outcomes of Early-Onset Sepsis in Very Preterm Infants: Results from the Thai Neonatal Registry (ThaiNy).Antibiotics (Basel, Switzerland) · 2026Article
- Antibiotic Prophylaxis and Treatment of Neonatal Group B Streptococcus Disease in the Era of Antimicrobial Resistance.Antibiotics (Basel, Switzerland) · 2026Review
- Research Progress on perinatalFrontiers in microbiology · 2026Review
- Antibiotic treatment for neonatal sepsis: changing trends and future directions.Drugs in context · 2026Review
- Antibiotic exposure and infection epidemiology among newborns with congenital diaphragmatic hernia.Journal of perinatology : official journal of the California Perinatal Association · 2025Observational
- Non-Susceptibility of Early-Onset Sepsis Pathogens to the Combination of Ampicillin and Gentamicin Among Neonates in Thailand.Antibiotics (Basel, Switzerland) · 2025Article
- Antibiotic use among extremely low birth-weight infants from 2009 to 2021: a retrospective observational study.Archives of disease in childhood. Fetal and neonatal edition · 2025Observational
- An Overview of Antibiotic Therapy for Early- and Late-Onset Neonatal Sepsis: Current Strategies and Future Prospects.Antibiotics (Basel, Switzerland) · 2024Review
- Sustaining the Continued Effectiveness of an Antimicrobial Stewardship Program in Preterm Infants.Tropical medicine and infectious disease · 2024Article
- Neonatal Sepsis: Aetiology, Pathophysiology, Diagnostic Advances and Management Strategies.Clinical medicine insights. Pediatrics · 2024Review
- Evolving antibiotic resistance in Group B Streptococci causing invasive infant disease: 1970-2021.Pediatric research · 2023Article
- Neonatal infections: Insights from a multicenter longitudinal research collaborative.Seminars in perinatology · 2022Article
- Early-Onset Neonatal Sepsis in Turkey: A Single-Center 7-Year Experience in Etiology and Antibiotic Susceptibility.Children (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundEmpiric administration of ampicillin and gentamicin is recommended for newborns at risk of early-onset sepsis (EOS). There are limited data on antimicrobial susceptibility of all EOS pathogens.
methodsRetrospective review of antimicrobial susceptibility data from a prospective EOS surveillance study of infants born ≥22 weeks' gestation and cared for in Neonatal Research Network centers April 2015-March 2017. Nonsusceptible was defined as intermediate or resistant on final result.
resultsWe identified 239 pathogens (235 bacteria, 4 fungi) in 235 EOS cases among 217,480 live-born infants. Antimicrobial susceptibility data were available for 189/239 (79.1%) isolates. Among 81 Gram-positive isolates with ampicillin and gentamicin susceptibility data, all were susceptible in vitro to either ampicillin or gentamicin. Among Gram-negative isolates with ampicillin and gentamicin susceptibility data, 72/94 (76.6%) isolates were nonsusceptible to ampicillin, 8/94 (8.5%) were nonsusceptible to gentamicin, and 7/96 (7.3%) isolates were nonsusceptible to both. Five percent or less of tested Gram-negative isolates were nonsusceptible to each of third or fourth generation cephalosporins, piperacillin-tazobactam, and carbapenems. Overall, we estimated that 8% of EOS cases were caused by isolates nonsusceptible to both ampicillin and gentamicin; these were most likely to occur among preterm, very-low birth weight infants.
conclusionsThe vast majority of contemporary EOS pathogens are susceptible to the combination of ampicillin and gentamicin. Clinicians may consider the addition of broader-spectrum therapy among newborns at highest risk of EOS, but we caution that neither the substitution nor the addition of 1 single antimicrobial agent is likely to provide adequate empiric therapy in all cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.